Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

George Zureikat

Pediatric Critical Care Medicine Flint, MI Medical Doctor

NPI 1891765426 CMS profile 40658

1 Hurley Plz, Flint, MI 48503

Open in the dashboard

General payments

$172,676

503 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, George Zureikat of Flint, MI is reported in the CMS Open Payments database as having received $172,676 across 503 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Pediatric Critical Care Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $45,044 140
2024 General $30,173 99
2023 General $62,354 116
2022 General $11,414 60
2021 General $15,201 54
2020 General $7,180 27
2019 General $1,310 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • George Zureikat
  • Pediatric Critical Care Medicine median
  • Middle half of Pediatric Critical Care Medicine
  • National median

In program year 2025, general payments to George Zureikat were reported at $45,044. Among 471 Pediatric Critical Care Medicine profiles paid that year, the median was $72 and the middle half received between $29 and $177.

Show as a table
Year George Zureikat Pediatric Critical Care Medicine median Middle half National median
2019 $1,310 $76 $21–$155 $163
2020 $7,180 $48 $21–$174 $114
2021 $15,201 $41 $19–$133 $132
2022 $11,414 $76 $25–$136 $149
2023 $62,354 $76 $25–$168 $160
2024 $30,173 $73 $24–$150 $164
2025 $45,044 $72 $29–$177 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Jazz Pharmaceuticals Inc. $111,782 219 payments
  2. Axsome Therapeutics, Inc. $25,238 61 payments
  3. Harmony Biosciences LLC $15,515 74 payments
  4. Idorsia Pharmaceuticals US Inc $15,033 25 payments
  5. Inspire Medical Systems, Inc. $2,379 12 payments
  6. Amgen Inc. $664 34 payments
  7. AstraZeneca Pharmaceuticals LP $570 16 payments
  8. GlaxoSmithKline, LLC. $352 16 payments
  9. Regeneron Healthcare Solutions, Inc. $168 5 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $152 6 payments
  11. Other $822 35 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $120,812 37 payments
  2. Consulting Fee $16,788 9 payments
  3. Travel and Lodging $13,197 55 payments
  4. Food and Beverage $12,846 391 payments
  5. Honoraria $6,875 3 payments
  6. Compensation for serving as faculty or as a speaker for a medical education program $1,650 1 payment
  7. Education $508 7 payments
Products named General payments · program years 2019–2025
  1. XYWAV $103,970 188 payments
  2. Sunosi $25,119 60 payments
  3. QUVIVIQ $15,033 25 payments
  4. WAKIX Narcolepsy $13,503 30 payments
  5. XYREM $7,445 20 payments
  6. WAKIX Narcoplepsy $1,334 12 payments
  7. INSPIRE $1,263 10 payments
  8. Inspire Upper Airway Stimulation System $1,116 2 payments
  9. TEZSPIRE $664 34 payments
  10. Wakix Neurological Disorders $600 29 payments
  11. Other $2,604 94 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

472

Median for Critical Care (Intensivists): 406

Drug cost

$19,444

Median for Critical Care (Intensivists): $197,260

Branded share of claims

12.9%

Median for Critical Care (Intensivists): 69%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Sunosi Solriamfetol Hcl Brand 12 $10,033
Modafinil Generic 48 $6,260
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 19 $763
Temazepam Generic 78 $573
Trazodone Hcl Generic 70 $556
Zolpidem Tartrate Generic 96 $436
Clonazepam Generic 90 $318
Pramipexole Dihydrochloride Pramipexole Di-Hcl Brand 30 $271
Montelukast Sodium Generic 13 $128
Gabapentin Generic 16 $104

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,531 Part D prescribers listed as Critical Care (Intensivists); they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 16 billing codes

Paid by Medicare

$60,555

Medicare's payments for the services billed

Medicare patients

308

Average age 71

Services billed

714

147 women, 161 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 46%
Diabetes 37%
Ischemic heart disease 32%
Chronic kidney disease 24%
Depression 24%
Atrial fibrillation 19%
Heart failure 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XYWAV
  • JAZZ PHARMACEUTICALS INC. $21,935
$21,935 — —
Sunosi
  • Axsome Therapeutics, Inc. $5,198
$5,198 12 —
WAKIX
  • Harmony Biosciences LLC $1,334
$1,334 — —
TEZSPIRE
  • Amgen Inc. $241
  • AstraZeneca Pharmaceuticals LP $64
$305 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $133
$133 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

503 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Critical Care Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record